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 A b s t r a c t 
 
Lung cancer is one of the most common cancers with small cell lung 
cancer (SCLC) representing 18% of the total lung cancer diagnoses. 
Conventional treatments include the administration of high dosages of cisplatin, 
but as most anti-cancer agents, this drug is not targeted which causes toxicity 
and undesirable severe side-effects which limit its clinical application. 
Liposome-based formulations have been recently exploited for improving the 
delivery and therapeutic effect of cisplatin (Lipoplatin®). In this study, we sought 
to generate a targeted liposomal formulation. The gastrin releasing peptide 
(GRP) receptor is over-expressed on many cancer cells including SCLC. A 
conventional liposomal cisplatin formulation was modified by adding a GRP 
receptor agonist to a pegylated lipid which was then inserted into pre-formed 
liposomes. However, the biological activity of peptide-modified liposomal 
cisplatin was comparable to the control liposomes when tested on GRP 
receptor positive SCLC cells (NCI-H345), and GRP receptor negative control 
cells (A549), using the MTS assay.  ICP-AES analysis of cisplatin encapsulation 
efficiency showed encapsulation to be decreased in the targeted formulation. 
Fluorescence liposomes were also prepared to evaluate the uptake of the cells, 
using carboxyfluorescein as fluorescence agent. Results shows higher uptake 
by target- liposomes. 
Keywords: 
Small-lung cancer, Bombesin, Liposome, Cisplatin, Fluorescence 
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1. Introduction 
According to the World Health Organization (WHO) is the major cause of 
death in developed countries in 2008 around 12.7 million new cancer cases 
were diagnosed worldwide resulting in 7.6 million deaths.[1, 2] Cancer is known 
medically as a malignant neoplasm, including a broad group of diseases, all 
involving unregulated cell growth. In cancer, cells divide and grow 
uncontrollably, forming malignant tumours, and invade nearby parts of the body. 
Cancer may also spread to more distant parts of the body through the lymphatic 
system or bloodstream.[1, 3] Determining the causes of cancer is complex. 
Many things are known to increase the risk of cancer, including tobacco use, 
certain infections, radiation, and lack of physical activity, obesity and 
environmental mental pollutants. [1] These can directly damage genes or 
combine with existing genetic faults within cells to cause the 
disease.  Approximately five to ten percent of cancers are entirely hereditary.[3] 
It is believed that for a normal cell to be converted into a cancer cell mutations 
have to take place at different sites. [4] Two types of genes are of particular 
importance in the development of cancer: oncogenes, the genes that cause a 
cancerous phenotype, and the tumour suppressor genes which protect the cells 
from the development of cancer.[3] The oncogenes are often mutated or 
overexpressed in cancer cells and the tumour suppressor genes have often lost 
their function due to mutation.[3, 4] The most commonly diagnosed cancers 
worldwide are lung, breast and colorectal cancer. It is estimated that 18% of 
lung cancer diagnosed is small-cell lung (SCLC) also known as oat cell 
cancer.[5] In 16-32% of SCLC cases there is an overexpression of MYC 
proteins.[6] Through the encoding of nuclear phosphoproteins the MYC is a 
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transcription factor that regulates the transcription of many target genes that, 
cause increased cell growth, and also cause cell cycle progression.[5, 6] 
Gastrin-releasing peptide (GRP), the human homologue of the amphibian 
peptide bombesin, has a role in embryonic development and adult repair of 
bronchial epithelia.[6] GRP and neuromedin B are both produced by SCLC cell 
lines and small cancer lung cells also express receptors for these two peptides 
as well as bombesin receptor subtype 3.[7] An autocrine-stimulated growth loop 
is observed due to the secretion of the peptides and the subsequent binding to 
their receptors and receptor activation.[6, 7] 
Chemotherapy is the treatment of cancer that uses anti-cancer drugs 
(ACD). It is often used with a curative intent or it may aim to prolong life to 
palliate symptoms.[8] Almost all the ACD are not target-specific, affecting all 
dividing cells therefore producing many side-effects.[9, 10] The ACD is 
classified according to their mechanism of action. In the case of SCLC the most 
commonly-used class of ACD is the alkylating agents, so-named because of 
their ability to alkylate many nucleophilic groups under conditions present in the 
cells.[10] Cisplatin and carboplatin are the most common alkylating 
chemotherapeutics used for the treatment of SCLC.[5] They impair cell function 
by forming covalent bonds with the amino, carboxyl and sulfhydryl groups in 
biologically important molecules. [10] Cisplatin forms stable adducts with DNA 
that are responsible for the drug’s anticancer activity. [11] It is believed that 
cisplatin reacts with N-7 of guanine and intrastrand cross-links are formed, in 
this way cisplatin causes DNA bending and unwinding followed eventually by 
apoptosis. [12] After cisplatin has entered the cell the drug undergoes aquation 
to form [Pt(NH3)2Cl(OH2)]+ and [Pt(NH3)2(OH2)2]2+ due to the low level of 
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chloride ions inside the cell. [13]The principal limitations for their use are due to 
its severe toxicities, especially nephrotoxicity, neuropathy, ototoxicity and 
haematological toxicities.[10, 11] 
For these reasons, an improved liposome formulation of cisplatin, 
Lipoplatin®, has been recently introduced in the clinical practice.[11]  
Lipoplatin (Liposomal cisplatin) is a liposome formulation containing cisplatin. 
[11, 12] The liposome is composed of a lipid shell made of dipalmitoyl-
phosphatidyl glycerol (DPPG), soy, phosphatidyl-choline (SPC/3), cholesterol 
(CHOL), methoxy-polyethylene, and glycol-distearoyl phophatidylethanolamine 
lipid conjugate (mMPEG2000-DSPE) in a ratio of cisplatin to lipids of 
aproximatelly 10% cisplatin and 90% lipids. [12, 14, 15] These liposomes 
contain cisplatin in the aqueous part. The PEG-coating increases the circulation 
of the lipoplatin formulation in vivo as preventing recognition by macrophages 
and immune cells favoring accumulation of the drug mainly in primary tumour 
sites and metasteses (EPR effect). [10, 11, 16] This accumulation of the drug in 
primary tumour is called passive targeting where the formulated drug makes 
use of the body’s already existing mechanisms to reach the target site, can be 
achieved by encapsulating the drug in liposomes and making the liposomes 
resistant to opsonisation by plasma proteins; they will removed slowly from the 
circulation by the Mononuclear Phagocyte System (MPS) system and the drug 
can then circulate in the body for a longer time and can also make use of the 
Enhanced Permeability and Retention (EPR) effect within the tumour 
microenvironment.[17] Many anti-cancer drugs used in the clinic today have 
severe toxicity profiles because of their mechanisms of action are not tumour-
specific and kill the healthy cells too.[18, 19] Liposomal formulations of anti-
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cancer drugs are one way to try to avoid these toxicity drawbacks.[18, 20, 21] 
Preparation of a liposomal formulation as anti-cancer drug has a number of 
advantages including extension of the drug circulation time, increases the 
probability of drug accumulation in the tumour site through using the EPR effect 
and a consequential reduction in the toxicity drawbacks side-effects.[16, 18] 
In order to make the drug delivery more specific different types of ligands 
can be coupled to the drug carrier. [21] Such ligands include antibodies, 
peptides, sugar moieties and folate.[22] Recent studies in nanomaterials have 
explored passive and active targeting strategies for enhancing intratumoral drug 
concentrations while limiting the unwanted toxicity to healthy tissues.[19]  
One way to actively directed nanocarriers to tumour cells is by targeting 
the receptors that are over-expressed on their surface. However, the presence 
of receptor-targeting moiety on PEGylated liposomes limits the cellular uptake 
of liposomes due to receptor saturation. Considering that an ideal tumor 
targeted drug delivery system should not only selectively targeted delivery 
drugs to tumor, but also deliver the drugs into tumor cells with high efficacy.[19] 
For SCLC this can be achieved targeting the GRP receptors with specific 
ligands such as gastrin-releasing peptides (GRP), bombesin peptides. which 
have shown high affinity for these receptors.[19] There are two different 
subtypes of bombesin receptors, a GRP-preferring bombesin receptor and a 
neuromedin B-preferring bombesin receptor. [22] Bombesin and GRP share a 
common C-terminal heptapeptide sequence.[8, 19] Since bombesin receptors 
are overexpressed by many tumours including SCLC  they can be used as 
targets for chemotherapeutics receptor-mediated tumor localization.[19] Studies 
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have shown specificity on the drug delivery and in use of therapeutic diagnostic 
using the bombesin like a target specific therapy.[19, 23]  
In this study we modified a liposomal formulation of cisplatin by adding a 
small percentage of a Bombesin-PEG2000-lipid able to specifically bind the GRP 
receptor and evaluated the response of targeted liposomes in receptor positive 
and receptor-negative cell line. The uptake of target and non-target liposomes 
was also evaluate using fluorescence target formulation in receptor-positive cell 
line. 
 
2. Materials and Methods 
2.1 Materials 
1.2-dioleoyl-sn-glycerol-3 phosphoethanolamine-N-[Methoxy 
(Polyethylenoglycol-2000] (ammonium salt) (mPEG 2000 – DSPE), 1,2 – 
dioleoyl–sn-glicero-3-phosphocoline (DOPC), 1,2-Diastearol-sn-glycero-3-
Phosphoethanolamine-N-[Maleimide (Polyethyleneglycol-2000] (ammonium 
salt) (mPeg 2000-DSPE), Cholesterol (ovine wal)>98% by Avanti Polar Lipids, 
USA. Cis-Diammineplatinum (II) dichloride, G 25 Sephadex Phenazine 
ethosulfate, 5-(and-6)-Carboxyfluorescein (CF) from Sigma-Aldrich, UK. 
Chloroform from Fisher Scientific, UK. RPMI 1640, Dubelco modified eagle 
media (DMEM) by Gibco life technologies, UK. Hyclone fetal bovine serum, 96 
microwell plate and T-75 flask by Thermo Scientific, UK. Penstrep  (10.000/mL 
penicillin and 10mg streptomycin/0.9%Nacl) and Trypsin/EDTA 
0.05%(0.25mg/100ml) by Gibco, Paisley, UK. CellTiter 96 AQueous MTS 
reagent powder. Promega, Southampton, UK. C-Bombesin (C-QWAVGHLM) 
peptide was generously donated by M. Giorgetti.  Equipaments: UV-visible 
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spectrometer, Perkin Elmer, Lambda 35; BD accuri, Malvern Nano-ZS instrument, 
Malvern Instruments Ltd., Worcestshire UK; POLARstar Optima; BMG Labtech-
Aylesbury, UK 
 
2.2 Methods 
2.2.1 A549 – cells  
The A549 cell line, derived from a lung adenocarcinoma was from ATCC, 
USA. A549 cells grow adherently and do not express the GRP – receptor. They 
were used as negative control cells in this project.  
A549 cells were maintained in DMEM medium with 10% FBS and 2% 
pen–strep in T-75 flasks. Cells were passaged washing with PBS followed by 
trypsinization. They were centrifuged (200 rcf, 5 min); the supernatant was 
removed and re-suspending in fresh media before passaging them onto either 
to 96 well plates or new flasks. Cultures were maintained in a water saturated 
incubator at 37 °C in an atmosphere of 95% air and 5% CO2. 
 
2.2.2- NCI – H345 – cells  
The NCI – H345 cell line derives from a small cell lung carcinoma. The 
cells grow as mulitcell aggregates in suspension and express the GRP receptor. 
 Cells were maintained in RPMI 1640 medium with 10% FBS and 2% 
pen–strep in T-75 flasks they were passaged once a week and feed with fresh 
full media three days after passage. Cells were passaged by centrifugation (200 
rcf, 5 min), removal of the supernatant and re-suspending in fresh media before 
passaging them onto either to 96 well plates or new flasks. One day after 
splitting the cells in the 96 well plates were treated with the different 
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formulations. Cultures were maintained in a water saturated incubator at 37 °C 
in an atmosphere of 95% air and 5 % CO2. 
 
 2.2.3 Synthesis of bomesin-PEG2000-DSPE lipid conjugate. 
35 mg of C-Bombesin (5 equivalents) was dissolved in 1mL DMSO and 
left at room temperature for one hour to complete dissolution. TCEP (bond 
breaker, Thermo Scientific) was added (1:100 v/v) and incubated for 1h to 
reduce any intramolecular disulfide bonds. 20 mg of DSPE-PEG2000 – 
Maleimide (1 equivalent) was added to the peptide solution and reacted under 
stirring for 3 days at room temperature. The DMSO solvent was removed under 
high vacuum and the product re-suspended in 2 ml of water before dialysis for 3 
days (MW 2,000) to remove unreacted peptide. Following dialysis the aqueous 
Bombesin-Peg2000-DSPE suspension was lyophilised. The resultant powder 
was dissolved in chloroform and kept at -18 °C.  The concentration of the 
DSPE-PEG2000-Bombesin chloroform was determined by UV spectroscopy. 100 
µL of the chloroform solution was diluted in 1 mL of chloroform and UV 
absorbance at 280 nm was measured on a UV-visible spectrometer (Perkin 
Elmer, Lambda 35). The total amount of Bombesin-Peg2000-DSPE was 
determinate by using the Lambert-Beer equation using as extinction coefficient 
5690.  
 
 2.2.5 Bombesin -PEG2000- DSPE insertion into pre-formed liposomes. 
Liposomes targeting ligands with 1% (57 DOPC:38 CHOL: 4 PEG2000: 1 
DSPE-PEG2000-Bombesin, molar ratio) and 4% (57 DOPC:38 CHOL: 1 PEG2000: 
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4 DSPE-PEG2000-Bombesin, molar ratio) of the total lipid formulation were 
prepared. 
An aliquot of the DSPE-PEG2000-Bombesin chloroform solution, 
equivalent to 1% or 4% (molar ratio) was dried under rotary evaporation and 
high vacuum to form a film. The film was hydrated with the standard liposomal 
suspension loaded with cisplatin or carboxyfluorescein as described above in 
2.3. The liposomal mixture was then heated at 60 °C for 1h to accelerate of the 
insertion of the micelles into the pre-formed liposomes.[24] Following heating, 
the liposomes were cooled on ice and the suspension dialyzed (MWCO 2.000) 
overnight against PBS, same osmolality as the liposomes, to remove any 
leaked cisplatin or carboxyfluorescein and unincorporated micellar bombesin-
PEG2000-DSPE from the external volume of the liposome suspension.  
 
 2.2.4 Liposome Preparation 
Liposomes formulations were composed of: DOPC:CHOL:Peg2000-DSPE 
(57:38:5 molar ratio).[25] For the Bombesin-Peg-DSPE, encapsulated with 
cisplatin, the molar ratio was 1 mol%, and encapsulated with carboxyfluorescein 
the molar ratio was 1 and 4 mol%.  
Liposomes were prepared by the film hydration method followed by 
sequential extrusion.[25, 26] Vesicles were prepared by evaporation of the 
solvent from a CHCl3 solution of the lipid; the dried lipid film was re-hydrated in 
a solution of cisplatin (1.5 mg/mL in RPMI culture medium) to obtain a final lipid 
concentration of 10 mg/ml. Control liposomes, without cisplatin, were prepared 
by re-hydrating film hydration in RPMI medium. The suspensions were vortexed 
until completely dispersion of the film and then freeze-thawed five times in liquid 
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nitrogen and 40 degree water bath.[27] The multi-lamellar polydisperse vesicles 
were then sized down by repeated extrusions (Liposofast, Avestin) at room 
temperature through polycarbonate membrane (Avestin).[25, 28] Three steps of 
twenty-one extrusions through filters of 0.2 mm, 0.1 mm and 0,05 mm pore 
sizes made the preparation of a narrow sized distribution of unilamelar 
vesicles.[25, 28] 
Cisplatin that was not entrapped inside the liposome was removed by 
size exclusion chromatography (SEC) with Sephadex G-25 microcolumn (1 ml-
syringe). The column was prepared by dispersing 1g of Sephadex G25 in 10 mL 
of RPMI. The mixture was left in the fridge overnight to swell the resin.[28] A 
cotton wool layer was inserted in the bottom of 1 mL syringes. The syringes 
were then filled with the Sephadex dispersion before they were placed in 15 mL 
Falcon tubes and centrifuged for 3-4 minutes at 2000 rcf.[28] After 
centrifugation more eluent was added and the falcon tubes containing the 
syringes were centrifuged again, 300 µL of liposome dispersions were eluted 
and centrifuged at 2000 g for three minutes without loss or dilution of 
material.[28] Cisplatin liposomes were passed 3 times through the column. 
The final concentration of the cisplatin inside the liposome was measured 
by inductively coupled plasma–atomic emission spectrometry (ICP-AES). We 
don`t have this equipment so the sample were sent to the analytical department 
to be analysed.  
Liposomes encapsulated with carboxyfluorescein were prepared by 
hydrating the dried film with 50 mM CF in 10 mM HEPES buffer at pH-7.4 and 
extruded as explained before. Non-encapsulated CF was separated from CF 
encapsulating liposomes using a Sephadex G-50 column using RPMI medium 
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as an eluent, which has the same osmolarity as the liposomes. They were 
passed 10 times through the column. 
CF leakage experiments were recorded using a Varian Cary Eclipse. The 
excitation and emission wavelengths were set to 480 nm and 520 nm, 
respectively.  
For CF we couldn`t precise the concentration, we just measure the final 
intensity inside the cells.  
 
2.2.6 Dynamic light scattering (DLS)  
DLS experiments were carried out on Malvern Nano-ZS instrument 
(Malvern Instruments Ltd., Worcestshire UK) and were analysed by Malvern 
Zetasizer 6.12 software. Measurements have been performed at 25 °C on 0.5 
mL samples previously transferred into the plastic the plastic cuvette. Samples 
were diluted 10 times in buffer before the measurement.  
 
 2.2.7 Zeta Potential 
Zeta potential measurements were carried out on Malvern Nano-ZS 
instrument (Malvern Instruments Ltd., Worcestshire UK) and analysed by 
Malvern Zetasizer 6.12 software. Folded capillary cells (Zetasizer) were used as 
measure cell.  Runs were performed at 25 °C with a current rate of 215.3 kcps 
on 1 mL of the sample diluted 10 times in buffer. 
 
2.2.8 MTS – assay  
The MTS assay was used for the A549 and the NCI-H345 to evaluate the 
cell viability. 40 mg of MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-
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carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) was dissolved 
in 20 mL of PBS 2:1 ratio (mg:mL; MTS:PBS) and 1.84 mg phenazine 
ethosulfate (PES) was dissolved in 2 mL of PBS in a 0.92:1 (mg:mL PES:PBS). 
The two solutions were then combined in a ratio of 20:1 (MTS:PES) and stored 
in dark containers at -20°C. To the culture wells containing cells in 0.2 mL of 
culture medium 20 μL of the MTS/PES solution were added.  After two hours, 
the amount reduced formazan produced was assayed by measuring the optical 
density at 492 nm using a spectrophotometer (POLARstar Optima; BMG 
Labtech-Aylesbury, UK). 
 
2.2.9 Flow cytometer-assay 
Flow cytometer assay was performed using NCI-H345 cells to evaluate 
the uptake of the target and non-target CF liposomes, using BD accuri C6 
equipment. 100.000 cells were incubating with different CF liposome 
formulation; non-target and target liposomes, 1 and 4mol% of Bombesin added.  
The cells were incubated with the formulations for two hours at 37 0C 5% CO2 
and at 4 0C. Liposomes that were not uptake by the cells were removed by 
washing them with cold isoosmolar PBS buffer.  
The washes were performed by centrifuging the cells at 4 oC for 8 
minutes at 12000 rcf removing the supernatant and re-suspending the cells in 
600 µL cold PBS buffer, this procedure was performed 3 times. The final cell 
suspension in PBS buffer was analysed by flow cytometer measuring 
fluorescence intensity, using the software BD accuri. 
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3. Results 
3.1 Characterization of control, cisplatin-loaded liposomes and CF 
liposomes 
Different liposomal formulation prepared were analysed by DLS and z-
potential. Table 1 report the physical characterization of the liposomes and the 
efficiency of encapsulation of the cisplatin inside the liposomes. Control 
liposomes containing no cisplatin (Figure 1b) and cisplatin-loaded liposomes 
(Figure 1c) were monodispersed, as can be seen by the size distribution by 
intensity reported in Figure 3a and 3b. The graphs show a low range of 
distribution of liposome size indicating low Polydispersity (PDI) that is confirmed 
by the results demonstrated on table 1.  
Results of physical characterization for CF liposomes are reported on 
table 1. Non-target and 1 mol% CF liposomes were monodispersed as can be 
seen by size distribution by intensity on Figure 3e and 3f, confirmed by the low 
PDI (table 1). However 4 mol% CF liposome had two populations as indicate by 
figure 3g , and confirmed by the elevate PDI (table 1). 
The zeta potential almost zero indicates the stability of the liposomes in 
the suspension. 
 
 
 
 
 
Figure 1 – Schemes of different liposomes formulation. 
a – Normal structure of liposome – vesicle composed of a lipid bilayer; b – Liposome 
Pegylated;                           
c – Liposome load with cisplatin/carboxyfluorescein (cisplatin liposome; CF liposomes);  
d – cisplatin/carboxyfluorescein liposome functionalized with Bombesin. 
a b c d 
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3.2 Synthesis and characterisation of Bombesin -PEG2000- DSPE 
Bombesin-PEG2000- DSPE was prepared for later insertion into the pre-
formed control pegylated liposomes loaded with cisplatin. The reaction is 
represented in Scheme 1. After the conjugation the product was purified by 
dialysis to remove unreacted peptide reactant. The Bombesin-PEG2000-DSPE 
was characterized by Matrix-Assisted Laser Desorption/Ionisation (MALDI) 
Time of Flight (TOF) mass spectrometry (MS). Figure 2 represents the 
spectrum of the final product.  The expected mass of the peptide is 3983.605 
Da and the spectrum shows a peak at m/z 3922.233 and 3966.266, this 
difference can be attributed by the difference on final molecular weight of the 
Peg2000-DSPE-maleimide that can be different of the one that we used to 
calculate because the polymerization reaction is hard to stop. On the spectrum 
(not shown this data) it was also detected the peptide and the Peg2000-DSPE-
maleimide but we assumed that almost everything was removed by dialysis and 
this amount represent a very small quantity. 
Attempts to characterise the purity of Bombesin -PEG2000- DSPE by 
reverse phase HPLC were unsuccessful due to suspected retention of the 
product on C18 and C8 columns (data not shown). 
After dissolution in chloroform the final concentration and therefore yield 
of the product was evaluated by UV-spectrophotometer. Final concentration of 
the Bombesin -PEG2000- DSPE solution was 1.849 mg/ml equating to an overall 
reaction yield of 90% which means that the reaction was almost completely 
having just 10% of lost in the process.  
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Scheme 1-Synthesis of the Bombesin -PEG2000- DSPE 
DSPE-PEG2000-maleimide (a) – was reacted with Cysteine modified bombesin (b) to 
give bombesin -PEG2000- DSPE (c) 
DMSO/ Room 
Temperature 3 
days 
c 
b 
a 
+ 
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Figure 2 - MALDI mass spectrum of Bombesin -PEG2000- DSPE 
 
3.3 Characterisation of Bombesin-modified liposomes. 
Bombesin-functionalized liposomes (Figure 1d) were prepared by adding 
the bombesin-PEG-lipid to preformed cisplatin-loaded liposomes or CF-load 
liposomes. As for control liposomes, the peptide modified liposomes were 
analysed by DLS.  This preparative method, consisting of 3 different steps, has 
been optimized to obtain a monodispersed liposome suspension and the size 
has been checked throughout the process as shown in Figure 3d. As we can 
see on the figure the peptide did not fuse with the liposomes immediately, only 
after heat up as we can observe by the increase size of the liposomes, however 
there is still peptide that didn`t incorporate the liposomes and they are going to 
be removed by dialysis for 24h. Thus, bombesin-functionalized liposomes were 
characterized by more complex size distributions where bigger agglomerates 
are observed in Figure 3c. The main population were the target liposomes but 
as we can observe on the picture there is still a second pick but it represents 
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less than 1% so we assume it was pure. However when 4mol% bombesin-PEG-
lipid was added we couldn`t manage to have an monodisperse liposome 
suspension as shown on figure 3f, even  extruding again with 200 nm and 100 
nm filter. 
 
4.4 Efficiency of cisplatin encapsulation  
Cisplatin encapsulation was lower than expected but it is reproducible for 
different replicates (n=3).  However, the encapsulation of cisplatin in Bombesin-
functionalised liposomes was half that of the control loaded liposomes.  
  
Table 1 
DLS analysis of Liposomes and efficiency of encapsulation. 
 Size  
(nm) 
PDI Zeta 
Potential 
(mV) 
Encapsulation  
Cisplatin (%) 
** 
Liposome Control 
(n=3) 
104.7±2.6 0.076±0.030 -1.48±1.03 n/a 
Cisplatin Liposome 
(n=3) 
101.3±1.9 0.093±0.018 -3.23±1.26 11.1±0.6 
Cisplatin Liposome + 1% 
Bombesin-DSPE-PEG (n=1)* 
121.6±3.9 0.421±0.037 -1.74±1.01 5.02 
CF Liposome 
(n=3) 
110.4±2.7 0.139±0.014 -1.15±0.012 n/a 
CF Liposome 1% Bombesin-
DSPE-PEG (n=2) 
126.1±1.5 0.213±0.001 -2.72±1.9 n/a 
CF Liposome 4% Bombesin-
DSPE-PEG (n=2)* 
329.6±5.8 0.461±0.035 -2.91±1.5 n/a 
n/a = not applicable; PDI = Polydispersity  
*Sample had multi-populations as can be seen on figure 3c and the 121nm represents the 
continuous peak that is most abundant population. 
**Encapsulation was calculated using the real concentration of the cisplatin solution used to 
prepare the liposomes compare with the real concentration of cisplatin find in the liposomes. 
Real concentration of cisplatin was given by ICP-AES analysis of the samples. 
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Figure 3 – DLS of different liposomal formulation prepared. The graphs represent the size 
distribution of the liposomes.        
          Cisplatin liposome without Bombesin-Peg2000-DSPE                
          Cisplatin liposome just after add the Bombesin-Peg2000-DSPE .              
          Cisplatin liposome-Bombesin after 1h at 60°C. 
          Cisplatin liposome-Bombesin after purification – Dialysis 24hrs. 
 
                                    
 
4.3. Cellular effect following incubation with conventional and Bombesin 
liposomes 
 In order to evaluate the effectiveness of the different formulations 
prepared MTS cell assay was performed, as described on section 2.3, on the 
two different cells lines used on this study NCI – H345 and A549.  
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Different concentrations of each formulation were added to the cells to 
evaluate the dose-response. Figure 4 represents how much cells were alive, 
cell viability, after exposed to different concentrations of the different 
formulations. Results with the liposome control, figure 4a and 4b, shows that 
this formulation didn`t have any effect on the cells and no IC50, half maximal 
inhibitory concentration of a substance, was calculated for them. For the others 
formulation IC50 was calculated and it is demonstrated on table 2. 
Evaluating the response of the cells to the others formulations the A549 
cells showed a dose-dependent response for cisplatin solution (figure 4d); H345 
shows a dose-response for the formulation too, (figure 4c) however the cell 
viability for the A549 was 1. For the cisplatin liposome the A549 show a lower 
dose-response effect having about 11% of cell viability; H345 shows a dose-
response for the formulation too, the response was almost the same as it was 
for the cisplatin solution, table 2 shows the results of IC50 calculated, that 
reflects the response of the cells showed in the graphs.  
Figure 5a and 5b represents the cell viability of the NCI-H345 and A549, 
respectively, when exposed to the cisplatin liposome-Bombesin formulation. As 
we can see the cell viability is 100% or more, which means that there was no 
effect of the formulation over the cells.  Although an IC50 value was not able to 
be calculated for the bombesin-liposome formulations it is clear from the trend 
in the cell viability graphs that the cisplatin did not significantly affect the viability 
of either cell line.  For example, the mean viability of A549 cells at the highest 
cisplatin concentration was 112% and for H345 199%.  
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Figure 4– Dose-response of the cells with different treatments. Results for three 
representatives experiments. GraphPad Prism 5 was used to acquire the data. 
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Table 2  
Results of IC50 from three representatives experiments. 
 
 IC50 
Cisplatin Liposome 
(µM) 
IC50 
Cisplatin Solution 
(µM) 
IC50 
Cisplatin 
Liposome-
Bombesin 
(µM) 
H345 0.00716±0.00055 
 
2.71±2.31 * 
A549 3.58±2.27 2.39±1.34 * 
    
*not possible to calculate 
 
 
 
 
 
 
 
 
Figure 5–Dose-response of the cells for target liposomes. Result of one representative 
experiment. 
 
4.4 Cellular effect following incubation with conventional and Bombesin 
CF liposomes 
The evaluation of the effectiveness of target and non-target CF 
liposomes was performed by flow cytometry assay in order to evaluate the 
uptake of the CF liposomes by NCI-H345 cell, as described on section 2.2.9. 
 Figure 6 represents the fluorescence intensity measure in the cells; 
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(figure 6b). With 4mol% Bombesin we had the lower uptake (figure 6c). Cells 
incubated at 4 °C had the lower uptake as it was expected. 
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Figure 6– Quantitative observation of effect of different amounts of Bombesin-PEG2000-DSPE 
on the uptake of CF liposomes by NCI-H345. 
 
 
4. Discussion 
The characterization of the liposomes showed a monodisperse liposome 
suspension with a slight negative zeta potential for all the three different 
formulations. The zeta-potential is almost zero indicating the stability of the 
suspension. On biological application nanoparticles should be  sized between  5 
a b 
c 
d 
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and 150 nm, smaller than 5 nm it will be removed very quickly by renal 
clearance and bigger than 150 nm can accumulate in the spleen, liver and bone 
marrow.[29] The mean size of the liposomes, control and cisplatin, that were 
prepared for the experiment were about 100nm and CF liposomes were about 
110 nm, except 4 mol% Bombesin that size was around 329 nm. The detection 
of a liposomal diameter greater than the pore diameter is common and happens 
because pegylated liposomes are more rigid structure making more difficult to 
reduce the size, but they are in the size range used in biomedical application. 
The Pegylation is a strategy used to reduce the formation of protein corona 
forming a `brush` that does not permit the proteins coat the liposomes. Other 
advantage of using Pegylated liposomes is because it has the ability to 
passively accumulate in tumour tissues through Enhanced Permeability and 
Retention (EPR) effects, however can lead to another problem that is reduce 
the extent of interaction with the target cells. [30] To overcome this problem 
ligands like peptides are added at the terminal ends of PEG moieties to produce 
active targeting PEG-liposomes.[30] The peptide attached to the liposomes on 
this study was a Bombesin analogue where an N-terminal cysteine was added 
to bombesin to enable conjugation to a maleimide functionalised pegylated 
DSPE lipid. This peptide was chosen because the SCLC expresses the 
receptor for Bombesin, the GRP. [6] The peptide has previously been shown to 
target specific-prostate-tumour that overexpresses the GRP receptor.[18] The 
study shows that if the peptide is conjugated with gold-nanoparticle it can be 
used as theranostics therapy because the target nanoparticle will accumulate 
on the specific tissue (prostate). [18] 
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Synthesis of the bombesin-Peg2000-DSPE conjugate was successful as 
demonstrated by analysing the molecular weight of the final product, that should 
be around 3983.605 g/mol (bombesin = 1043 PEG2000-DSPEmaleimide = 
2940.605) . The MALDI-TOF spectrum shows a range of different molecular 
weights close to average molecular mass (44 g/mol). The broad range of 
spectral peaks is due to the presence of a range of polymeric moieties, each 
separated by ABC Daltons, which represents one ethylene glycol unit. This 
happens because the PEG2000 component of the DSPE-PEG2000-maleimide is 
polymeric and the polymerization reaction is very hard to stop leading to some 
of the polymers have more molecules of ethylene glycol than others.  
The post-insertion method used to fuse the peptide into the liposomes is 
described in section 3.4. It involves the application of pre-formed liposomes to a 
thin film of peptide-PEG-DSPE. To achieve the final formulation, some steps 
have to be performed.  When the liposome suspension is added to the 
Bombesin-Peg2000-DSPE film it is expected that the peptide-PEG-lipid will form 
micelles in the aqueous suspension and that fusion of micelles with the 
liposomes will produce a colloidal mixture where the targeting peptide resides 
only on the outer leaflet of the liposome. Immediately after hydration of the film 
we observed no difference in DLS analysis of the liposomes, which can mean 
that the micelles didn’t incorporate the liposomes immediately. To induce the 
fusion of the micelles with the liposomes a heating step was performed.[24] 
After heating to 60 degrees it was possible to see that the liposomal suspension 
was no longer monodispersed, because not all the micelles had incorporated 
into the liposomes. To remove any excess of lipid-peptide not encapsulated in 
the liposomes we dialysed the sample against an isoosmolar buffer for 24 hrs. 
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DLS results showed that the most abundant size population was similar to the 
cisplatin-loaded liposomes before hydration of the thin film and so micelle 
incorporation was presumed to have occurred. For CF liposomes we have 
similar results when added 1 mol% Bombesin-Peg2000-DSPE, but when added 4 
mol% Bombesin-Peg2000-DSPE there were two populations, even after dialysis 
and extruding again the liposomes we were not able to reduce the size and 
have a monodisperse suspension. This could be attributed to the fact that in 
higher concentration is harder to the peptide attach the liposomes because is 
more difficult to find space on the surface of the liposomes and is very common 
have an accumulation of peptide in one side of the liposomes surface. [19] 
Figure 3f shows the size distribution of the liposomes with big size and having 
two populations making harder the entrance in the cells because the liposomes 
are two times bigger than the recommended for biological use and will probably 
be eliminated by renal clearance or will be recognized by macrophages two 
things that we should avoid in a formulation. [31] 
Dose response cytotoxicity studies were performed on NCI-H345 and 
A549 cells. The viability of the cells was evaluated by MTS assay after 72 hrs, 
which is a standard time scale of exposure for anti-cancer drugs.[32] Liposome 
control, with no encapsulated cisplatin, did not show any toxic effect on the cells 
while cisplatin solution and cisplatin-loaded liposomes have a dose-dependent 
response. A549 showed almost the same response to the both formulations, 
while for the H345 the liposome formulation is more effective, as shown by the 
lower IC50 on Table 2. However these results are not striking because of the 
low efficiency of encapsulation of the cisplatin (Table 1) and an optimization on 
the process needs to be performed.  As we can observe in figure 4 the NCI 
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H345 is more resistance cell line than A549 using the highest concentration of 
cisplatin there is less than 10% of cell viability and for the NCI H345 using the 
same concentration we have more than the double of cell viability. It was 
already been reported that NCI H345 (SCLC) have resistance for the 
chemotherapy, one of the options to increase the response to the treatment is 
use multi-drug treatment, but still is not enough to cure the disease. [6, 33, 34] 
The resistance of the NCI H345 on the chemotherapy treatment is one of the 
main reasons to develop a target formulation and increase the delivery of the 
drug inside the cells increasing the cells death.  
Bombesin-functionalized liposomes loaded with cisplatin were tested and 
didn`t show to effect for both cell lines used. It was expected not to have an 
enhanced effect on A549 cells because the cells do not expresses the GRP 
receptor which would allow NCI-H345 cells to internalise greater numbers of 
liposomes through GRP receptor-mediated endocytosis. Effect on the NCI H345 
was expected since these cells should express the GRP receptor and hence to 
be targeted. We speculate that the low encapsulation efficiency of cisplatin in 
the targeted liposomes explain the poor outcome from the MTS assay. As 
mentioned above, cisplatin encapsulation efficiency was very low also in the 
control formulations and needs optimization. For the cisplatin-liposome-
Bombesin the encapsulation efficiency decreased by 50% with respect to the 
control compromising the outcomes from the biological results. However, we 
cannot rule out that the bombesin-functionalized liposomes are not specifically 
interacting with the GRP receptor expressed on the cells. If the Bombesin is not 
being recognized by the GRP receptor the liposomes are not entering inside the 
cells, and no dose-response effect will be observed. A third hypothesis is that 
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the NCI H345 cells do not express the GRP receptor in our hands. This is less 
likely as the over-expression of the GRP-receptor has been reported in the 
literature. [21]  
Flow cytometer simultaneously measure and then analyse multiple 
physical characteristic of singles particles including size, relative granularity or 
internal complexity and fluorescence intensity. [31, 35] In this study we use this 
method to evaluate the uptake of the liposomes by cells measuring the 
fluorescence intensity.  
Since cisplatin liposomes didn`t show goods results we use a 
fluorescence agent, CF to load the liposomes and investigate enhanced uptake 
into NCI-H345. As we can see on section 4.4 the results using fluorescence 
target liposomes were the ones that we expected since the beginning of the 
work, target liposomes had bigger uptake by the cells than the non-target, 
control liposomes, as it can be seen on figure 6c.  The results showed better 
uptake when 1 mol% Bombesin was added. It was already been described on 
literature that the concentration of the peptide on the formulation is a critical 
point. [19] Two reasons can explain that, one was already been discussed, 
about the size of liposomes  and the other one is that the receptor could 
saturated blocking the entrance of the liposomes inside the cells. 
Concentrations lower than 1 mol% and between 1 and 4 mol% should be tested 
to determinate the ideal concentration of the peptide to be attached on 
liposomes, use different concentration of peptide will also show if the bad 
results using 4 mol% Bombesin was the saturation of the receptor or it was the 
formulation that should be optimized. 
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Comparing percentage of liposomes added and temperature we could 
see that 1 mol% Bombesin at 37 oC have the higher uptake different from the 
results when liposomes were load with cisplatin. Target cisplatin-liposomes 
didn`t showed good results when it was tested on the cells and we suggest that 
the cells were not expressing the GRP receptor, but after analyse results 
obtained using CF liposomes we could visualized that the target liposomes 
worked. This results gives more support to the hypothesis that the target 
cisplatin liposomes didn`t worked because of the lower encapsulation of the 
drug. Next steps of the work should be optimize the encapsulation of cisplatin, 
or use another drug, and optimize the concentration of Peg2000-DSPE-Bombesin 
added to the liposome. In the present work others concentrations were not 
tested because the amount of peptide that we had was not enough. 
Experiments using scrambled peptide should also be done as well to evaluate 
the specificity of the peptide that we are using. 
5. Conclusion 
Liposomes were prepared and used on the experiments performed on 
the cells. The encapsulation of the cisplatin inside the liposomes presents to be 
a problem, having a lower percentage of encapsulation especially with cisplatin 
liposome-Bombesin. The lower encapsulation of the cisplatin reflect on the 
results of the cell viability assays. Fluorescence liposomes were prepared to 
investigate the uptake by the receptor-positive cells and evaluate if target 
liposomes have more uptake than non-target. Experiments were successfully 
executed with 1 mol% Bombesin liposome having the best uptake. The next 
step is try add different concentrations of Bombesin on the formulation to find 
the ideal concentration and optimize cisplatin load inside liposomes. 
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Description 
.The European Journal of Pharmaceutics and Biopharmaceutics provides 
a medium for publication of novel and innovative research from the areas of 
Pharmaceutical Technology, Pharmaceutical Biotechnology and 
Biopharmaceutics. 
Topics covered include: 
• Drug and pro-drug design, drug stability and drug development; 
• Development, formulation and manufacturing of pharmaceuticals and 
biopharmaceuticals; 
• Physical pharmacy, drug delivery systems, controlled release systems 
and drug targeting; 
• Biopharmaceutics; 
• Pharmaceutical analysis and pharmaceutical packaging; 
• Quality control, GMP and regulatory aspects; 
• Medical devices; 
"The Rules of 3" 
The Editors and Editorial board have developed the "Rules of 3". Authors 
must consider the following three criteria before they submit a manuscript and 
set the whole process of editing and reviewing at work: 
1. The paper must report on recent advances in pharmaceutical 
technology, biopharmaceutics and pharmaceutical biotechnology of major 
importance  
2. A paper must be based on a thorough and extensive study, using 
established or well-described methods and including proper controls. Research 
must be hypothesis-driven and conclusions must be supported by the data 
presented. 
3. The study described in the manuscript must represent a novel 
approach 
Audience 
.Pharmaceutical Scientists, Chemical Engineers, Pharmaceutical and 
Biopharmaceutical Scientists, Medicinal Chemists, Pharmacologists, Analytical 
Chemists, Clinical Pharmacologists, Pharmaceutical Engineers. 
Impact factor 
. 
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2012: 3.826 © Thomson Reuters Journal Citation Reports 2013 
Abstracting and indexing 
MEDLINE® 
International Pharmaceutical Abstracts 
PASCAL M 
CAB Abstracts 
BIOSIS/Biological Abstracts 
Chemical Abstracts Service 
EMBASE/Excerpta Medica 
Scopus 
Science Citation Index Expanded 
Language (usage and editing services) 
Please write your text in good English (American or British usage is 
accepted, but not a mixture of these). Authors who feel their English language 
manuscript may require editing to eliminate possible grammatical or spelling 
errors and to conform to correct scientific English may wish to use the English 
Language Editing service available from Elsevier's WebShop 
(http://webshop.elsevier.com/languageediting/) or visit our customer support 
site(http://support.elsevier.com) for more information. 
Submission 
Submission to this journal proceeds totally online and you will be guided 
stepwise through the creation and uploading of your files. The system 
automatically converts source files to a single PDF file of the article, which is 
used in the peer-review process. Please note that even though manuscript 
source files are converted to PDF files at submission for the review process, 
these source files are needed for further processing after acceptance. All 
correspondence, including notification of the Editor's decision and requests for 
revision, takes place by e-mail removing the need for a paper trail. 
Referees 
You are requested to name at least 5 international experts as possible 
reviewers for your manuscript, providing their names, affiliations and email 
addresses. 
 
References 
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There are no strict requirements on reference formatting at submission. 
References can be in any style or format as long as the style is consistent. 
Where applicable, author(s) name(s), journal title/book title, chapter title/article 
title, year of publication, volume number/book chapter and the pagination must 
be present. Use of DOI is highly encouraged. The reference style used by the 
journal will be applied to the accepted article by Elsevier at the proof stage. 
Note that missing data will be highlighted at proof stage for the author to 
correct. 
Formatting requirements 
There are no strict formatting requirements but all manuscripts must 
contain the essential elements needed to convey your manuscript, for example 
Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, 
Artwork and Tables with Captions. 
If your article includes any Videos and/or other Supplementary material, 
this should be included in your initial submission for peer review purposes. 
Divide the article into clearly defined sections. 
Figures and tables embedded in text 
Please ensure the figures and the tables included in the single file are 
placed next to the relevant text in the manuscript, rather than at the bottom or 
the top of the file. 
Materials and methods 
It should include materials, standard techniques and procedures relevant 
to the study. Published procedures and techniques should be cited unless 
significant modifications are involved. Exact specification of relevant materials 
and equipment must be given. Chemical terms must conform with IUPAC rules. 
Trademarks of commercial products must be labelled using a superscripted '(r)'. 
Names of products and equipment mentioned in the Materials and Methods 
section must be accompanied by the name of the manufacturer or distributor, 
location and state or country. This information must be stated in parentheses in 
the text, and not as a footnote. Any potential hazards connected with materials 
and procedures must be mentioned. A precise and detailed description should 
be given of those steps which are of vital importance in carrying out any 
repetition of the work. The Declarations of Helsinki and Tokyo for humans, and 
the European Community guidelines as accepted principles for the use of 
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experimental animals, must be adhered to. Therefore, EJPB will only consider 
manuscripts that describe experiments that have been carried out under 
approval of an institutional or local ethics committee. Authors must state in 
the manuscript that the protocol complies with the particular 
recommendation and that approval of their protocols was obtained. 
Equations must be part of the text and consecutively numbered on the 
right hand side using numbers in parentheses. References to equations in the 
text are also to be made with parentheses, e.g. using Eq. (3), etc. 
Organic formulas, both in figures and in the text, should be numbered in 
boldface arabic numerals. 
SI units must be used throughout. 
Results 
Results may be presented in tables, figures or schemes which must be 
referred to in the accompanying text, using appropriate numbering, e.g. Fig. 1, 
Table 2. 
Discussion 
It should focus on the interpretation of the results. It might be appropriate 
to combine RESULTS AND DISCUSSION in one section. If necessary at all, 
use CONCLUSIONS only to illustrate the general implication of the results and 
do not summarize the previous text. 
Conclusions 
The main conclusions of the study may be presented in a short 
Conclusions section, which may stand alone or form a subsection of a 
Discussion or Results and Discussion section. 
Appendices 
If there is more than one appendix, they should be identified as A, B, etc. 
Formulae and equations in appendices should be given separate numbering: 
Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. 
Similarly for tables and figures: Table A.1; Fig. A.1, etc. 
Essential title page information 
• Title. Concise and informative. Titles are often used in information-
retrieval systems. Avoid abbreviations and formulae where possible. 
• Author names and affiliations. Where the family name may be 
ambiguous (e.g., a double name), please indicate this clearly. Present the 
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authors' affiliation addresses (where the actual work was done) below the 
names. Indicate all affiliations with a lower-case superscript letter immediately 
after the author's name and in front of the appropriate address. Provide the full 
postal address of each affiliation, including the country name and, if available, 
the e-mail address of each author. 
• Corresponding author. Clearly indicate who will handle 
correspondence at all stages of refereeing and publication, also post-
publication. Ensure that phone numbers (with country and area code) are 
provided in addition to the e-mail address and the complete postal 
address. 
Contact details must be kept up to date by the corresponding 
author. 
• Present/permanent address. If an author has moved since the work 
described in the article was done, or was visiting at the time, a 'Present address' 
(or 'Permanent address') may be indicated as a footnote to that author's name. 
The address at which the author actually did the work must be retained as the 
main, affiliation address. Superscript Arabic numerals are used for such 
footnotes. 
It should contain a brief and clear description of the aim of the paper, its 
principal results and major conclusions (100--200 words). The abstract should 
include all keywords pertinent to the subject. 
Graphical abstract 
A Graphical abstract is mandatory for this journal. It should summarize 
the contents of the article in a concise, pictorial form designed to capture the 
attention of a wide readership online. Authors must provide images that clearly 
represent the work described in the article. Graphical abstracts should be 
submitted as a separate file in the online submission system. Image size: 
please provide an image with a minimum of 531 × 1328 pixels (h × w) or 
proportionally more. The image should be readable at a size of 5 × 13 cm using 
a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or 
MS Office files. See http://www.elsevier.com/graphicalabstracts for examples. 
Authors can make use of Elsevier's Illustration and Enhancement service 
to ensure the best presentation of their images also in accordance with all 
technical requirements: Illustration Service. 
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Keywords 
Indicate 5 to 10 English keywords. They should be carefully selected in 
order to improve accessibility of scientific information in the manuscript. 
Keywords commonly used in international abstracting services will be preferred. 
Chemical compounds 
You can enrich your article by providing a list of chemical compounds 
studied in the article. The list of compounds will be used to extract relevant 
information from the NCBI PubChem Compound database and display it next to 
the online version of the article on ScienceDirect. You can include up to 10 
names of chemical compounds in the article. For each compound, please 
provide the PubChem CID of the most relevant record as in the following 
example: Glutamic acid (PubChem CID:611). The PubChem CIDs can be found 
via http://www.ncbi.nlm.nih.gov/pccompound. Please position the list of 
compounds immediately below the 'Keywords' section. It is strongly 
recommended to follow the exact text formatting as in the example below: 
Chemical compounds studied in this article 
Ethylene glycol (PubChem CID: 174); Plitidepsin (PubChem CID: 
44152164); Benzalkonium chloride 
(PubChem CID: 15865) 
More information is available at: http://www.elsevier.com/PubChem. 
Abbreviations 
Define abbreviations that are not standard in this field in a footnote to be 
placed on the first page 
of the article. Such abbreviations that are unavoidable in the abstract 
must be defined at their first 
mention there, as well as in the footnote. Ensure consistency of 
abbreviations throughout the article. 
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Figures 
Figures must be presented on separate sheets in consecutive order 
using Arabic numerals. Each figure should be provided with an instructive title 
and explanatory information. The legend should be typed separately from the 
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figures. To ensure identification of the figures, indicate figure number and name 
of author using soft pencil. Submit original drawings in black ink on good quality 
white paper. 
High-contrast photographs are equally acceptable. One original set is 
required with the submission. 
Numbering and lettering of figures should be carefully accepted in order 
to ensure readability after photographic reduction of the figure. Use only 
standard symbols to mark datapoints. Explanation of curves and symbols 
should be in the legend rather than part of the drawing, unless this is 
detrimental to clarity. Indicate SI units of measure in parentheses. 
Colour illustrations should be submitted as original photographs, high-
quality computer prints or transparancies, close to the size expected in 
publication or as 35 mm slides. Polaroid colour prints are not suitable. If, 
together with your accepted article, you submit usable colour figures then 
Elsevier will ensure , at no additional charge, that these figures will appear in 
colour on the web (e.g., ScienceDirect and other sites) regardless of whether or 
not these illustrations are reproduced in colour in the printed version. For colour 
reproduction in print, you will receive information regarding the total cost from 
Elsevier after receipt of your accepted article. For more detailed instructions 
please visit our artwork instruction pages at 
http://www.elsevier.com/artworkinstructions. 
Tables 
Tables must be presented on separate sheets in consecutive order using 
Arabic numerals. The table headings must include a descriptive title and 
additional information to make the table self-explanatory. 
Some information may be given by using lower-case letter designations 
referring to footnotes at the bottom of the table. Indicate SI units of measure in 
parentheses. 
References 
References must be arranged as follows: 
[1] A.– L. Cornaz, P. Buri, Nasal mucosa as an absorption barrier, Eur. J. 
Pharm. Biopharm. 40 (1994) 261– 270. 
[5] C. Lanczos, Applied Analysis, Prentice-Hall, Englewood Cliffs, NJ, 
1967, pp. 272– 280. 
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[10] D.M. Barends, Stability of active ingredients, in: H. Mü ller, W.H. 
Oeser (Eds.), Drug Master Files, Wissenschaftliche Verlagsgesellschaft mbH, 
Stuttgart, Germany, 1992, pp. 121– 128. 
[14] E.A. Balazs, Ultrapure hyaluronic acid and the use thereof, U.S. 
Patent 4,141,973 (1979). 
The system used by Chemical Abstracts (Chemical Abstracts Service 
Source Index) must be followed for the abbreviations of journals. Reference (4) 
is for patents, including the status, international country code, number of patent 
and year. 
Articles in Special Issues: Please ensure that the words 'this issue' are 
added (in the list and text) to any references to other articles in this Special 
Issue. 
Citation in text 
Please ensure that every reference cited in the text is also present in the 
reference list (and vice versa). Any references cited in the abstract must be 
given in full. Unpublished results and personal communications are not 
recommended in the reference list, but may be mentioned in the text. If these 
references are included in the reference list they should follow the standard 
reference style of the journal and should include a substitution of the publication 
date with either 'Unpublished results' or 'Personal communication'. Citation of a 
reference as 'in press' implies that the item has been accepted for publication. 
Web references 
As a minimum, the full URL should be given and the date when the 
reference was last accessed. Any further information, if known (DOI, author 
names, dates, reference to a source publication, etc.), should also be given. 
Web references can be listed separately (e.g., after the reference list) under a 
different heading if desired, or can be included in the reference list. 
References in a special issue 
Please ensure that the words 'this issue' are added to any references in 
the list (and any citations in the text) to other articles in the same Special Issue. 
Reference management software 
This journal has standard templates available in key reference 
management packages EndNote 
(http://www.endnote.com/support/enstyles.asp) and Reference Manager 
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(http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing 
packages, authors only need to select the appropriate journal template when 
preparing their article and the list of references and citations to these will be 
formatted according to the journal style which is described below. 
